PRELIMINARY DATA ON SERUM OSTEOPROTEGERIN AND RANKL LEVELS IN PATIENTS WITH MYELOPROLIFERATIVE NEOPLASMS (MPNS)
EHA Library, Annita-Ioanna Gkioka, 4210062
ASSOCIATION BETWEEN JAK2V617F ALLELE BURDEN, CLINICAL FORMS, AND THROMBOEMBOLIC RISK GROUPS IN POLYCYTHEMIA VERA.
EHA Library, Fidan Khalilova, 4210066
REAL LIFE OUTCOME OF MOMELOTINIB IN PATIENTS  WITH PRIMARY OR SECONDARY MYELOFIBROSIS: PRELIMINARY RESULTS OF A RETROSPECTIVE EXPERIENCE OF TWO PUGLIA CENTERS
EHA Library, Anna Mele, 4210067
IMPACT OF BONE RESORPTIVE INHIBITORS ON DISEASE, SKELETAL, AND TREATMENT-RELATED OUTCOMES IN HISTIOCYTIC DISORDERS
EHA Library, Katherine Chapis, 4210072
AGE AS A PROGNOSTIC FACTOR IN ADULT POLYCYTHEMIA VERA: A MULTICENTER REAL-WORLD STUDY
EHA Library, Jian Huang, 4210074
WHOLE-EXOME SEQUENCING IN JAK2 UNMUTATED ERYTHROCYTOSIS: A STUDY OF A COHORT FROM A TERTIARY REFERENCE HOSPITAL
EHA Library, Ningning Liu, 4210076
BEYOND DONATION: HARNESSING ROUTINE CBCS FOR EARLY DETECTION OF MYELOPROLIFERATIVE NEOPLASMS
EHA Library, Juan Pablo Macías Flores, 4210078
TREATMENT DISRUPTION DURING THE INTERNATIONAL PEGYLATED INTERFERON SHORTAGE: RESULTS OF AN INTERNATIONAL PATIENT SURVEY IN MYELOPROLIFERATIVE NEOPLASMS
EHA Library, Llywelyn Cadman-Davies, 4210082
A PHASE 2/3 STUDY OF ELENESTINIB IN ISM: A TRIAL-IN-PROGRESS UPDATE OF NOVEL ENDPOINTS AND BIOMARKERS AIMED AT EVALUATING DISEASE MODIFICATION (HARBOR)
EHA Library, Jens Panse, 4210083
DOES HAPLOIDENTICAL TRANSPLANTATION IMPROVE MYELOFIBROSIS OUTCOMES IN REAL-WORLD? A SINGLE-CENTER EXPERIENCE FROM THE BRAZILIAN PUBLIC HEALTH CARE SYSTEM
EHA Library, Lucas Sales, 4210085
DEVELOPMENT OF EXPERT CONSENSUS ON THE MANAGEMENT OF MYELOFIBROSIS PATIENTS WITH ANAEMIA AND/OR THROMBOCYTOPENIA: A MODIFIED DELPHI PANEL
EHA Library, Gabriela Hobbs, 4210090
MORTALITY AND OUTCOMES AFTER CARDIOPULMONARY RESUSCITATION AND AFTER INTENSIVE CARE IN SWEDISH MYELOPROLIFERATIVE NEOPLASM PATIENTS
EHA Library, Helna Pettersson, 4210091
LANGERHANS CELL HISTIOCYTOSIS AND OTHER HISTIOCYTOSIS: A SINGLE CENTRE EXPERIENCE
EHA Library, Marianna Criscuolo, 4210094
PREVALENCE OF THROMBOSIS AND CARDIOVASCULAR RISK FACTORS IN PATIENTS WITH POLYCYTHAEMIA VERA; A MULTI CENTRE DESCRIPTIVE ANALYTICAL STUDY IN THE WESTERN PROIVINCE OF SRI LANKA
EHA Library, Ahalyaa Sivashangar, 4210095
DEMOGRAPHIC, CLINICAL CHARACTERISTICS OF BCR/ABL NEGATIVE MYELOPROLIFERATIVE NEOPLASMS PATIENTS IN OMAN, SINGLE CENTER EXPERIENCE
EHA Library, Zahra ALGhammari, 4210097
MOLECULAR REMISSION IN THE TREATMENT OF POLYCYTHEMIA VERA: SHORT-TERM EFFECT OF ROPEGINTERFERON ALFA2-B
EHA Library, Veronica Vecchio, 4210099
REAL-WORLD OUTCOMES OF MYELOFIBROSIS IN AN UNDERREPRESENTED LATIN AMERICAN POPULATION: EARLY EXPERIENCE FROM THE HOSPITAL GENERAL DE MÉXICO DR. EDUARDO LICEAGA
EHA Library, Gilberto Israel Barranco Lampon, 4210100
SAFETY AND EFFICACY OF RUXOLITINIB TREATMENT IN PATIENTS WITH MYELOFIBROSIS - A SINGLE-CENTER EXPERIENCE
EHA Library, Petra Belohlavkova, 4210101
REAL WORLD OUTCOMES OF TREATMENT WITH RUXOLITINIB FOR POLYCYTHAEMIA VERA PATIENTS AT A SINGLE CENTRE DISTRICT GENERAL HOSPITAL
EHA Library, Tanveer Hamid, 4210102
ACUTE CORONARY SYNDROME IN ESSENTIAL THROMBOCYTHEMIA: A CASE SERIES AND CLINICAL INSIGHTS
EHA Library, Marta Hernández Durán, 4210104
DEEP LEARNING-ENHANCED BASELINE PET FOR PROGNOSTIC PREDICTION IN CLASSICAL HODGKIN LYMPHOMA: A RETROSPECTIVE STUDY
EHA Library, Jingyan Xu, 4210106
FROM LONG‑TERM BENEFIT TO RISK‑STRATIFIED MANAGEMENT: A 5‑YEAR REAL‑WORLD MULTICENTER STUDY OF PD‑1 INHIBITORS IN CHINESE RELAPSED/REFRACTORY HODGKIN LYMPHOMA
EHA Library, Wenyan Yu, 4210107
FRONTLINE THERAPY AND OUTCOMES OF CLASSICAL HODGKIN LYMPHOMA IN MALAYSIA: A NATIONWIDE MULTICENTRE REAL-WORLD COHORT
EHA Library, Yang Liang Boo, 4210108
SPATIAL TRANSCRIPTOMICS OF THE HODGKIN LYMPHOMA MICROENVIRONMENT: TAM CLUSTERS AND IMMUNE CHECKPOINTS
EHA Library, Lily Filatova, 4210117
AHOD2131: A RANDOMIZED PHASE 3 INTERIM RESPONSE ADAPTED TRIAL COMPARING STANDARD THERAPY WITH IMMUNO-ONCOLOGY THERAPY FOR CHILDREN AND ADULTS WITH NEWLY DIAGNOSED STAGE I/II CLASSIC HODGKIN LYMPHOMA.
EHA Library, Boyu Hu, 4210118
FIRST-LINE NIVOLUMAB-AVD FOR EARLY-STAGE UNFAVORABLE AND ADVANCED-STAGE CLASSICAL HODGKIN LYMPHOMA: A META-ANALYSIS
EHA Library, Fernando Gibran-Nunes, 4210121
IMPACT OF CLINICAL TRIAL ELIGIBILITY ON SURVIVAL IN PATIENTS WITH ADVANCED-STAGE HODGKIN LYMPHOMA
EHA Library, Tayfur Toptas, 4210125
CHARACTERISTICS OF MICROSATELLITE INSTABILITY IN NODULAR SCLEROSIS CLASSICAL HODGKIN LYMPHOMA
EHA Library, Dmitry Diakonov, 4210126
INFLAMMATION-BASED SCORES AND THEIR DYNAMIC CHANGES AS PROGNOSTIC INDICATORS IN CLASSICAL HODGKIN LYMPHOMA
EHA Library, Hakki Onur Kirkizlar, 4210127
INDIVIDUALIZED MANAGEMENT OF RELAPSED OR REFRACTORY CLASSICAL HODGKIN LYMPHOMA IN A RESOURCE-LIMITED SETTING: A SINGLE-CENTER UKRAINIAN EXPERIENCE
EHA Library, Anisiia Luchkiv, 4210128
DIMINISHED PROGNOSTIC VALUE OF INTERIM PET IN HODGKIN LYMPHOMA TREATED WITH BRENTUXIMAB VEDOTIN PLUS AVD: A RETROSPECTIVE ANALYSIS
EHA Library, Kareem Latif, 4210131
A REAL-WORLD ANALYSIS OF FIRST LINE NIVOLUMAB COMBINED WITH DOXORUBICIN, VINBLASTINE, AND DACARBAZINE (N-AVD) IN CLASSICAL HODGKIN LYMPHOMA (CHL) – A SINGLE CENTER COHORT STUDY
EHA Library, Liat Shargian, 4210133
IMPACT OF INTERIM PET/CT AND DISEASE STAGING ON PROGRESSION AND TREATMENT TRAJECTORIES IN HODGKIN LYMPHOMA: A SINGLE CENTER COHORT STUDY.
EHA Library, Nikola Lemajic, 4210136
SEVERE AND LIFE-THREATENING POLYMORPHIC CUTANEOUS TOXICITY DURING BEGEV SALVAGE THERAPY FOR RELAPSED/REFRACTORY HODGKIN LYMPHOMA: A 9-CASE SERIES
EHA Library, Habiba Bennesser Alaoui, 4210137
THERAPEUTIC OUTCOMES OF ABVD VERSUS ESCALATED BEACOPP IN BULKY MEDIASTINAL HODGKIN LYMPHOMA: A SINGLE-CENTER TUNISIAN EXPERIENCE
EHA Library, Khouloud Mezghani, 4210144
HIGH DISCORDANCE BETWEEN CT AND PET ALTERS THERAPEUTIC STRATEGY IN HIGH-RISK HODGKIN LYMPHOMA: EVIDENCE FROM A PET-GUIDED REAL-WORLD COHORT
EHA Library, Nesrine Ben Sayed, 4210145
CLINICAL PROFILE, MANAGEMENT, AND EARLY OUTCOMES OF CLASSICAL HODGKIN LYMPHOMA: A REAL-WORLD DATA FROM A SINGLE-CENTER SERIES (2019–2024)
EHA Library, Malek Benakli, 4210147
ANALYSIS OF THIRD-LINE TREATMENT OUTCOMES IN PATIENTS WITH RELAPSED/REFRACTORY MANTLE CELL LYMPHOMA FOLLOWING FRONTLINE BENDAMUSTINE/RITUXIMAB AND SECOND-LINE BTK INHIBITOR THERAPY
EHA Library, Christine Ryan, 4210149
TREATMENT OF HIGH-RISK WALDENSTRÖM MACROGLOBULINEMIA IN PATIENTS OVER 65 YEARS OF AGE
EHA Library, Alexander Grachev, 4210152
BREAST IMPLANT–ASSOCIATED LYMPHOMA: SURFACE TEXTURE AND SURVIVAL OUTCOMES IN A TEN-YEAR SYSTEMATIC REVIEW
EHA Library, KALYSTA BORGES, 4210153
INTENSIFICATION OF THERAPY FOR WALDENSTRÖM'S MACROGLOBULINEMIA IN PATIENTS UNDER 65 YEARS OF AGE WITH UNFAVORABLE PROGNOSTIC FACTORS
EHA Library, Alexander Grachev, 4210155
REAL-WORLD OUTCOMES OF BISPECIFIC ANTIBODIES IN OLDER PATIENTS WITH RELAPSED/REFRACTORY (R/R) FOLLICULAR LYMPHOMA (FL)
EHA Library, Jessica Allen, 4210157
QUALITY OF LIFE OUTCOMES WITH TAFASITAMAB + LENALIDOMIDE AND RITUXIMAB FOR RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA (R/R FL): RESULTS FROM THE PHASE 3, DOUBLE-BLIND, PLACEBO-CONTROLLED INMIND STUDY
EHA Library, Paolo Strati, 4210158
UTILIZATION OF NOVEL AGENTS IN MANTLE CELL LYMPHOMA: RESULTS FROM A MULTI‑SITE PROSPECTIVE COHORT STUDY (SUMMIT)
EHA Library, Jakub Svoboda, 4210161
BENEFITS OF RITUXIMAB MAINTENANCE AFTER FIRST-LINE BENDAMUSTINE-RITUXIMAB IN PATIENTS WITH MANTLE CELL LYMPHOMA: A META-ANALYSIS OF CLINICAL TRIALS AND OBSERVATIONAL STUDIES
EHA Library, Julia Wang, 4210174
UTILITY OF NEXT-GENERATION SEQUENCING (NGS) IN PHILADELPHIA-NEGATIVE MYELOPROLIFERATIVE NEOPLASMS
EHA Library, Concepción Sánchez Chamizo, 4210063
SYSTEM-WIDE VARIABILITY IN SECONDARY POLYCYTHEMIA MANAGEMENT: A NATIONWIDE ENTROPY-BASED ANALYSIS
EHA Library, Sinan Mersin, 4210064
EXPLORATORY MACHINE LEARNING–BASED IDENTIFICATION OF PREDICTORS OF DISEASE PROGRESSION AND MORTALITY IN POLYCYTHEMIA VERA
EHA Library, Giulia Benevolo, 4210065
EFFECTS OF LONG-TERM HYDROXYUREA THERAPY ON BONE MARROW MEGAKARYOCYTE MORPHOLOGY AND ITS CORRELATION WITH PROGNOSIS IN PATIENTS WITH ESSENTIAL THROMBOCYTHEMIA AND POLYCYTHEMIA VERA
EHA Library, Jian Huang, 4210070
CLINICAL AND MOLECULAR CHARACTERISTICS AND PROGNOSTIC ANALYSIS OF ADULT POLYCYTHEMIA VERA: A MULTI-CENTER COHORT STUDY
EHA Library, Jian Huang, 4210073
REAL-WORLD (RW) CHART REVIEW OF CYTOREDUCTIVE THERAPY (CRT) PATTERNS, ADVERSE EVENTS AND TREATMENT MODIFICATIONS IN POLYCYTHEMIA VERA (PV) ACROSS PHYSICIAN PRACTICE SETTINGS IN THE US
EHA Library, Naveen Pemmaraju, 4210075
NEUTROPHIL-TO-LYMPHOCYTE RATIO AS AN INFLAMMATORY MARKER IN POLYCYTHEMIA VERA PATIENTS TREATED WITH ROPEGINTERFERON ALFA-2B
EHA Library, Bianca Nistor, 4210077
DESIGN VERIFICATION TESTING OF A HIGHLY SENSITIVE MULTIPLEX QPCR ASSAY THAT DETECTS THE JAK2 V617F VARIANT COMMONLY PRESENT IN MYELOPROLIFERATIVE NEOPLASMS
EHA Library, Jonathan Turner, 4210079
REAL WORLD DATA ON SAFETY AND EFFICACY OF ROPEGINTERFERON ALPHA-2B FOR THE TREATMENT OF POLYCYTHEMIA VERA
EHA Library, Thomas Thomopoulos, 4210080
CO-DESIGN OF A DIGITAL RESOURCE FOR PATIENTS WITH MYELOPROLIFERATIVE NEOPLASM ASSOCIATED SPLANCHNIC VEIN THROMBOSIS (MPN-SVT) AND CLINICIANS INVOLVED IN THEIR CARE
EHA Library, Mallika Sekhar, 4210081
VALIDATION OF TRIPLE A SCORE IN POLYCITEMIA VERA IN A SINGLE PORTUGUESE CENTER
EHA Library, Maria Inês Pinto, 4210084
UNMASKING DIABETES MELLITUS IN PATIENTS WITH BCR::ABL1 NEGATIVE MYELOPROLIFERATIVE NEOPLASMS USING CONTINUOUS GLUCOSE MONITORING
EHA Library, Josipa Budimir, 4210086
CLINICAL OUTCOMES OF MOMELOTINIB IN A REAL-WORLD COHORT OF PATIENTS WITH MYELOFIBROSIS
EHA Library, Esther Ortega Vida, 4210087
CORRELATION OF MEGAKARYOCYTE MORPHOLOGY WITH ADVERSE PROGNOSIS IN ESSENTIAL THROMBOCYTHEMIA
EHA Library, Jian Huang, 4210088
DIAGNOSTIC AND THERAPEUTIC INEQUITIES IN PHILADELPHIA-NEGATIVE MYELOPROLIFERATIVE NEOPLASMS: A MULTINATIONAL LATIN AMERICAN PHYSICIAN SURVEY
EHA Library, Carlos Murilo Barbosa Junior, 4210089
DISPARITIES IN TREATMENT MANAGEMENT AND OUTCOMES OF WHITE AND NON-WHITE ADOLESCENTS AND YOUNG ADULTS WITH MYELOPROLIFERATIVE NEOPLASMS.
EHA Library, Shruti Gajjar, 4210092
PRESENTATION AND MANAGEMENT OF PRIMARY MYELOFIBROSIS IN AZERBAIJAN: A RETROSPECTIVE NATIONAL CENTRE ANALYSIS
EHA Library, Elmir GULUYEV, 4210093
SENTRY2—A PHASE II STUDY EVALUATING SELINEXOR MONOTHERAPY IN PATIENTS WITH JAKI-NAÏVE MYELOFIBROSIS AND MODERATE THROMBOCYTOPENIA
EHA Library, Joseph M Scandura, 4210096
THE RATIONALE FOR THE ROUTINE USAGE OF NEXT GENERATION SEQUENCING (NGS) METHOD FOR DETECTION OF ADDITIONAL MUTATIONS IN ESSENTIAL THROMBOCYTHEMIA PATIENTS-SINGLE CENTRE EXPERIENCE
EHA Library, Marija Popova Labachevska, 4210098
JAK2-POSITIVE HYPEREOSINOPHILIC SYNDROME PRESENTING WITH VASCULAR AND GI
COMPLICATIONS
EHA Library, Rogermar VIllanueva, 4210103
NODULAR LYMPHOCYTE PREDOMINANT HODGKIN'S LYMPHOMA WITH TRANSFORMATION TO DIFFUSE LARGE B-CELL LYMPHOMA
EHA Library, Elena Dorokhina, 4210109
LUNG FUNCTION ASSESSMENT BY DIFFUSING CAPACITY OF THE LUNGS FOR CARBON MONOXIDE (DLCO) MEASUREMENT IN PATIENTS WITH CLASSICAL HODGKIN LYMPHOMA RECEIVING FIRST-LINE TREATMENT WITH NIVOLUMAB-AVD
EHA Library, Athanasios Liaskas, 4210111
GENOMIC INSTABILITY IN CLASSICAL HODGKIN LYMPHOMA: ASSOCIATION WITH METABOLIC TUMOR BURDEN AND CIRCULATING TUMOR DNA DETECTABILITY.
EHA Library, Anna Kravtsova, 4210112
LP-IPS–BASED RISK STRATIFICATION IN NODULAR LYMPHOCYTE-PREDOMINANT HODGKIN LYMPHOMA: A NINE-CENTRE TURKISH COHORT
EHA Library, Taner Tan, 4210113
NIVOLUMAB IN FIRST-LINE THERAPY FOR THRLBCL-LIKE PATTERN OF NODULAR LYMPHOCYTE PREDOMINANT HODGKIN LYMPHOMA
EHA Library, Elena Dorokhina, 4210115
OUTCOMES OF PEDIATRIC HODGKIN LYMPHOMA PATIENTS TREATED WITH ABVD REGIMEN. A RETROSPECTIVE COHORT STUDY
EHA Library, Hani Abdel Rahman Sayed, 4210116
PROGNOSTIC IMPACT OF THE SIMPLIFIED GERIATRIC ASSESSMENT IN OLDER PATIENTS WITH CLASSICAL HODGKIN LYMPHOMA
EHA Library, Vittorio Ruggero Zilioli, 4210119
OPTIMIZATION OF FIRST-LINE THERAPY IN PATIENTS WITH ADVANCED CLASSICAL HODGKIN LYMPHOMA: EFFICACY AND TOXICITY OF N-AVD COMPARED WITH EBEACOPP IN PROSPECTIVE CLINICAL TRIAL. REAL CLINICAL PRACTICE
EHA Library, Diana Ivanova, 4210120
PEGYLATED LIPOSOMAL DOXORUBICIN IN HEAVILY PRETREATED ADULT PATIENTS WITH CLASSICAL HODGKIN LYMPHOMA: REAL-WORLD DATA FROM GUSTAVE ROUSSY COHORT
EHA Library, Cristina Garcia-Herce, 4210122
SARCOPENIA IN OLDER PATIENTS WITH CLASSICAL HODGKIN LYMPHOMA: PROGNOSTIC AND TOXICITY-RELATED IMPACT IN A REAL-WORLD COHORT
EHA Library, Silvia Ferrari, 4210123
PROGNOSTIC UTILITY OF THE C-REACTIVE PROTEIN– ALBUMIN–LYMPHOCYTE (CALLY) INDEX IN HODGKIN LYMPHOMA
EHA Library, fatma keklik karadag, 4210124
INTERIM AND END-OF-TREATMENT (EOT) PET/CT ASSESSMENT AFTER NIVOLUMAB, DOXORUBICIN, VINBLASTINE, AND DACARBAZINE (N-AVD) IN ADVANCED-STAGE CLASSICAL HODGKIN LYMPHOMA (CHL): A SINGLE-CENTER EXPERIENCE
EHA Library, Alexia Piperidou, 4210129
PET GUIDED TREATMENT FOR NEWLY DIAGNOSED ADVANCED HODGKIN LYMPHOMA
EHA Library, Fatima Lamraoui, 4210132
BRENTUXIMAB VEDOTIN-BASED THERAPY FOR RELAPSED/REFRACTORY HODGKIN LYMPHOMA IN CHINA: A REAL-WORLD, MULTICENTER ANALYSIS
EHA Library, Nan Zhong, 4210134
REAL-WORLD CLINICAL CHARACTERISTICS, TREATMENT PATTERNS AND OUTCOMES OF CLASSICAL HODGKIN LYMPHOMA IN A MULTI-ETHNIC ASIAN POPULATION: A 15-YEAR SINGLE-CENTRE EXPERIENCE
EHA Library, Roni Wang, 4210135
REAL-WORLD TOLERABILITY AND PRELIMINARY ANALISYS OF EFFICACY OF BRECADD IN ADVANCED-STAGE HODGKIN LYMPHOMA: A MULTICENTER BRAZILIAN EXPERIENCE
EHA Library, Talita Silveira, 4210139
PREDICTIVE ROLE OF NEUTROPHIL TO LYMPHOCYTE (NLR) AND PLATELET TO LYMPHOCYTE RATIO (PLR) IN NEWLY DIAGNOSED HODGKIN LYMPHOMA
EHA Library, Andrijana Kojic, 4210140
THERAPEUTIC EFFICACY AND SAFETY OF THE TUNISIAN NATIONAL LH 2015 PROTOCOL FOR HODGKIN LYMPHOMA: A 9-YEAR RETROSPECTIVE MONOCENTRIC STUDY
EHA Library, Nesrine Ben Sayed, 4210142
FRONTLINE ABVD IS STILL FEASIBLE IN ADVANCED STAGE HODGKIN LYMPHOMA AS EARLY STAGE: A RETROSPECTIVE REAL-WORLD COHORT STUDY FROM TURKEY
EHA Library, Derya Demirtas, 4210143
REFRACTORY/RELAPSED HODGKIN LYMPHOMA IN CHILDREN: EXPERIENCE OF THE PEDIATRIC CLINICAL HEMATOLOGY DEPARTMENT AT AZIZA OTHMANA HOSPITAL
EHA Library, Lamia Issaoui, 4210146
THE USE OF PEMBROLIZUMAB AS MONOTHERAPY AND IN COMBINATION WITH CHEMOTHERAPY IN THE TREATMENT OF RELAPSED/REFRACTORY CLASSICAL HODGKIN LYMPHOMA
EHA Library, Bibigaisha Adusheva, 4210148
REAL-WORLD EFFECTIVENESS AND SAFETY OF ZANUBRUTINIB IN WALDENSTRÖM MACROGLOBULINEMIA: RESULTS FROM THE BELGIAN WIZARD STUDY
EHA Library, Willem Daneels, 4210150
RETREATMENT IN PATIENTS WITH MANTLE CELL LYMPHOMA: A SWEDISH LYMPHOMA REGISTER STUDY
EHA Library, Sandra Lockmer, 4210151
EFFICACY AND SAFETY OF NEMTABRUTINIB IN RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA: COHORT G OF THE PHASE 2 BELLWAVE-003 STUDY
EHA Library, Wojciech Jurczak, 4210154
MRD-DRIVEN TRIPLET THERAPY WITH ORELABRUTINIB, POMALIDOMIDE, AND ZUBERITAMAB FOR NEWLY DIAGNOSED INTERMEDIATE/HIGH-RISK MANTLE CELL LYMPHOMA
EHA Library, Ping Yang, 4210156
BRIDGING GAPS IN MANTLE CELL LYMPHOMA (MCL) MANAGEMENT: COMPARISON OFCOVALENT BTK INHIBITOR (CBTKI) USAGE AMONG EXPERTS AND HEALTHCARE PROFESSIONALS (HCPS)
EHA Library, Kemi Obajimi, 4210159
TREATMENT PATTERNS AND CLINICAL OUTCOMES IN CNS INVOLVEMENT OF MANTLE CELL LYMPHOMA (MCL) WITH PRIOR BTK INHIBITOR EXPOSURE; AN INTERNATIONAL RETROSPECTIVE STUDY.
EHA Library, Chan Y. Cheah, 4210160
ASSOCIATION OF MONOCLONAL PROTEIN WITH PLASMACYTIC DIFFERENTIATION AND POOR PROGNOSIS IN MARGINAL ZONE LYMPHOMA: A SINGLE-CENTER COHORT STUDY
EHA Library, Wei Wang, 4210162
REAL-WORLD EFFICACY OF ULTRA-LOW DOSE "BOOM BOOM" RADIOTHERAPY IN INDOLENT B-CELL LYMPHOMAS: PREDICTORS OF RESPONSE AND TIME TO NEXT TREATMENT
EHA Library, Avishag Cohen, 4210163
EPCORITAMAB WITH LENALIDOMIDE AND RITUXIMAB IN CHINESE PATIENTS WITH RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA: A SUBGROUP ANALYSIS FROM THE PHASE 3 EPCORE FL-1 TRIAL
EHA Library, Rong Tao, 4210166
NAVIGATING THE POST–COVALENT BRUTON TYROSINE KINASE INHIBITOR LANDSCAPE IN MANTLE CELL LYMPHOMA: REAL-WORLD INSIGHTS ON TREATMENT PATTERNS, DISCONTINUATION, AND HEALTHCARE RESOURCE UTILIZATION
EHA Library, Toby A. Eyre, 4210167
FIRST-LINE OBINUTUZUMAB PLUS CHEMOTHERAPY IN FOLLICULAR LYMPHOMA: A POLISH RESEARCH LYMPHOMA GROUP (PLRG) REAL-WORLD STUDY
EHA Library, Ewa Paszkiewicz-Kozik, 4210168
THERAPY OF FOLLICULAR LYMPHOMA TAKING INTO ACCOUNT RISK FACTORS – A VECTOR FOR IMPROVING TREATMENT RESULTS
EHA Library, Ekaterina Gitelzon, 4210170
REAL-WORLD OUTCOMES OF LISOCABTAGENE MARALEUCEL IN PATIENTS WITH RELAPSED AND/OR REFRACTORY MANTLE CELL LYMPHOMA
EHA Library, Sally Jones, 4210171
HEPATOBILIARY MALT LYMPHOMA: EXPANDING THE CLINICAL SPECTRUM OF A RARE EXTRANODAL MARGINAL ZONE LYMPHOMA
EHA Library, Benedikt Pelzer, 4210173

Anonymous User Privacy Preferences

Strictly Necessary Cookies (Always Active)

MULTILEARNING platforms and tools hereinafter referred as “MLG SOFTWARE” are provided to you as pure educational platforms/services requiring cookies to operate. In the case of the MLG SOFTWARE, cookies are essential for the Platform to function properly for the provision of education. If these cookies are disabled, a large subset of the functionality provided by the Platform will either be unavailable or cease to work as expected. The MLG SOFTWARE do not capture non-essential activities such as menu items and listings you click on or pages viewed.


Performance Cookies

Performance cookies are used to analyse how visitors use a website in order to provide a better user experience.



Google Analytics is used for user behavior tracking/reporting. Google Analytics works in parallel and independently from MLG’s features. Google Analytics relies on cookies and these cookies can be used by Google to track users across different platforms/services.



{$cookies-google-tag-manager-description}


Save Settings